Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

DECEMBER 28, 2023

In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Major research hospitals such as Montefiore in New York now use cannabis for treating cancer and HIV, as well as make new studies.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Major research hospitals such as Montefiore in New York now use cannabis for treating cancer and HIV, as well as make new studies.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

MMJ Recs

DECEMBER 17, 2023

Here’s some insight into what the program involves: Intractable Epilepsy Focus: The TCUP is highly focused, primarily catering to individuals diagnosed with one of a specific number of qualifying conditions (more on this below). Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Greencamp

AUGUST 16, 2018

In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Exploring the available research on ALS and cannabinoids. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies).

Strains 94

Strains Cannabinoids Research and Development Indica 94

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

The Joint Blog

JANUARY 12, 2020

However, researchers warn that not only are not all CBD pet products made equally, but some contain no CBD at all. You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag: He studies therapeutic uses for the compound.

Pets 36

Pets CBD Clinical Trials Research and Development 36

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Cannabis Law Report

SEPTEMBER 6, 2021

The steadily aging population across the globe has played a significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

SEPTEMBER 22, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman Bio.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

MARCH 2, 2020

The government said it is working with industry to explore further ways to reduce costs and encourage more research into uninterrupted access to cannabis-based medicinal products where clinically appropriate. By October 29, less than five patients had successfully obtained medicinal cannabis. But we still have a long way to go.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., Moreover, the FDA has also allowed researchers to conduct CBD trials. But things have changed after FDA eased out regulations in 2015 to carry out CBD trials.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. Instead, it would be helpful to encourage these companies to develop a greater understanding in the UK.”. CBD Testers.co

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. potential impact on structural and functional brain development. Recommendations. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! government classified all cannabis varieties, including hemp, as Schedule I under the Controlled Substances Act (despite decades of agricultural research detailing its differences from marijuana). What makes CBD special? In 1970, the U.S. CBD & Epidiolex.

CBD 99

CBD DEA Research and Development Hemp 99

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Marijuana law reform advocates and many medical researchers have been fighting to change marijuana’s Schedule I classification for years. Schedule I classification typically pertains to narcotic substances with no medical value.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

MMJ Recs

DECEMBER 22, 2023

Historically, marijuana was vilified and classified as a Schedule I controlled substance, which hindered both research and public acceptance. One of the key drivers of this shift is the increasing body of scientific research highlighting the medical properties of cannabinoids, the active compounds in marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. Preliminary research has also shown that CBD has the potential to help patients with Parkinson’s and Alzheimer’s diseases. That’s why some people choose THC oil. THC Oil Benefits. THC Oil Effects.

Oil 104

Oil THC Cannabinoids Research and Development 104

Cannabis Law Report

APRIL 10, 2019

These include “to initiate a process evaluation to address barriers” and to ask “the National Institute for Health Research and the industry to take action to produce … evidence in a form that will support decisions about public funding.”. The Secretary of State for Health and Social Care (Matt Hancock).

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

FEBRUARY 3, 2022

CBD oils have various health benefits in treating medical disorders like epilepsy, anxiety, cancer, acne, diabetes, and others. Product Development Via Research and Novel Product Delivery Solutions. Researchers Are Studying New Uses of Medical Marijuana. Clinical Trials of Cannabis Are Still on Going.

Indica 52

Indica Oil Legalization Research and Development 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

DECEMBER 7, 2021

Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. Introduction. Adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 1, 2021

Drake is well-known as an inspiring and inclusive leader who is dedicated to the development of her teams and solely focused on organizational success for the benefit of patients. Company remains on track for potential approval of Vicineum™ in the US in August 2021. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Mack, Chairman and CEO of Virpax.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 15, 2019

ACM takes in consideration the characteristics of medical cannabis preparations and substances, and is a simplified version of the marketing authorization required for medicinal products to some extent (for instance, no clinical trials are required). Regardless all these regulatory developments, what did change, in fact?

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52